Super gonorrhea is curable, but it’s harder to treat than regular gonorrhea and sometimes requires multiple rounds of antibiotics or alternative drug combinations. The term refers to strains of gonorrhea that have developed resistance to most or all of the antibiotics traditionally used against them, including the current last-resort treatment. Even in the most resistant cases documented so far, doctors have eventually cleared the infection, though it can take longer and demand close follow-up.
What Makes Super Gonorrhea Different
Standard gonorrhea is treated with a single injection of the antibiotic ceftriaxone. For decades, gonorrhea has steadily evolved resistance to one antibiotic class after another: penicillins, tetracyclines, fluoroquinolones, and eventually the older generation of drugs in the same class as ceftriaxone. Super gonorrhea strains carry mutations that make them resistant to ceftriaxone itself, which is currently the only CDC-recommended treatment for uncomplicated gonorrhea.
The bacteria accomplish this through genetic changes that alter the proteins antibiotics normally target. Some mutations change the shape of the bacterial cell wall proteins that ceftriaxone binds to, making the drug less effective. Others activate molecular pumps that push antibiotics back out of the bacterial cell before they can do their job. When a single strain accumulates enough of these mutations, it becomes resistant to multiple drug classes at once. The World Health Organization lists drug-resistant gonorrhea among its high-burden resistant pathogens, and surveillance has expanded from 4 countries in 2022 to 13 countries across 5 WHO regions in 2024, reflecting growing global concern.
How Resistant Cases Are Treated
When ceftriaxone alone doesn’t work, doctors turn to combination therapy, pairing different antibiotics to overwhelm the bacteria’s defenses. One well-studied backup approach pairs gentamicin (an older injectable antibiotic) with a high-dose oral antibiotic from a different class. Gentamicin has been used as a first-line gonorrhea treatment in Malawi for over 15 years without significant resistance emerging, and the bacteria remain susceptible to it across Europe as well. That track record makes it a reliable option when standard treatment fails.
If your initial treatment doesn’t clear the infection, your doctor will take a bacterial culture rather than relying on the standard DNA-based screening test. Cultures allow the lab to grow the bacteria and test them directly against a panel of antibiotics to find one that works. This process, called susceptibility testing, identifies exactly which drugs your specific strain is vulnerable to. It takes a few days longer than a standard test, but it’s the only way to guide treatment for a resistant case.
New Antibiotics in Development
Two new antibiotics designed specifically for drug-resistant gonorrhea are nearing approval, which would be the first new class of gonorrhea drugs in decades.
Zoliflodacin completed phase 3 trials with a cure rate of 90.9% for urogenital gonorrhea, compared to 96.2% for the current standard regimen. For harder-to-treat throat infections, zoliflodacin cured 79.2% of cases. The FDA set a target decision date of December 15, 2024, and approvals are also being sought in South Africa and Thailand. Because zoliflodacin works through an entirely different mechanism than existing antibiotics, it should be effective against strains that resist ceftriaxone.
Gepotidacin, another new drug, showed a 92.6% cure rate for urogenital gonorrhea in its phase 3 trial published in The Lancet. Side effects were mostly mild gastrointestinal symptoms like nausea and diarrhea, with no serious drug-related complications. Having two new antibiotics with different mechanisms would give doctors meaningful backup options and reduce the pressure on any single drug.
What Happens After Treatment
For standard gonorrhea, you typically don’t need a follow-up test unless symptoms persist. Resistant cases are different. If there’s any suspicion that treatment failed, you’ll return for a test of cure, which involves a culture-based test rather than the quicker screening method. This is because only a culture can confirm the bacteria are truly gone and test whether they’re still resistant.
Symptoms of gonorrhea, whether resistant or not, usually include painful urination, unusual discharge, or in some cases no symptoms at all. When treatment works, symptoms typically resolve within a few days, though you should avoid sexual contact until testing confirms the infection has cleared. Reinfection from an untreated partner is common, which is why the CDC recommends that sexual partners also receive treatment.
Risks of Delayed Treatment
The real danger with super gonorrhea isn’t that it can’t be cured. It’s that resistance can delay effective treatment, giving the infection time to cause damage. In women, untreated gonorrhea can lead to pelvic inflammatory disease, ectopic pregnancy, and infertility. In men, it can cause painful scrotal swelling, scarring of the urethra, and infertility. These complications develop over weeks to months of untreated infection, not days, so catching and addressing treatment failure quickly is critical.
Resistant strains also pose a broader public health risk. Every person carrying a resistant infection who continues having sexual contact can spread that strain further. Gonorrhea is one of the most common sexually transmitted infections worldwide, and the bacteria’s remarkable ability to swap genetic material means resistance genes can spread rapidly through a population. The faster resistant cases are identified and treated, the less opportunity these strains have to become dominant.